Seven of the top 10 global pharmaceutical products in 2014 will require cold-chain handling, contributing to a boom in the facilities, vehicles and packaging for this specialized function of the logistics industry.
For biopharma manufacturers, increased cold-chain shipments translate to process changes for the management of regulatory and reporting requirements, according to the Cold Chain Biopharma Logistic http://www.pharmaceuticalcommerce.com
“There are a growing number of validated technologies and transportation process options, particularly for real-time monitoring of a shipment’s condition,” says Nick Basta, co-author of the report. “Compliance officers and supply chain managers have many choices, and need not assume any longer that just because a shipment might be worth millions of dollars, it needs to have high-expense logistics service.”
Basta also points out that not all biologics require cold-chain handling, nor are all small-molecule products free of the requirement. “But when you look at how national and international regulations are evolving, you see that even room-temperature products will soon require additional monitoring steps that add complexity to the transportation process.”
“Biopharma Cold Chain Sourcebook 2010” is available from Pharmaceutical Commerce at info@pharmaceuticalcommerce.com.
